论文部分内容阅读
作者在国内首先制备了骨钙素(BGP)的抗血清,建立了BGP放射免疫测定方法。该抗血清特异性和灵敏度高,其最小检出量IC_(50)为2.5μg/L,批内差异<2.5％,批间差异<10.0％。应用本法测定了338例正常人和100例骨质疏松、糖尿病、卵巢切除、骨肿瘤、慢性肾功能衰竭、佝偻病和甲状旁腺功能亢进症患者血清BGP水平。骨质疏松BGP水平大多数下降,甲状旁腺功能亢进症、骨肿瘤者则明显升高,因此,血清BGP放免测定是骨病、代谢性骨病诊断和研究的一个重要检测手段。
The authors first prepared osteosarcoma (BGP) antisera in China and established a method of radioimmunoassay. The antiserum has high specificity and sensitivity. The minimum detectable amount of IC50 is 2.5μg / L, the intra-assay difference is less than 2.5% and the inter-assay difference is less than 10.0%. This method was used to determine serum BGP levels in 338 normal subjects and 100 patients with osteoporosis, diabetes, ovariectomy, bone tumors, chronic renal failure, rickets and hyperparathyroidism. Most of osteoporosis BGP levels decline, hyperparathyroidism, bone tumors were significantly higher, therefore, serum BGP radioimmunoassay is bone disease, metabolic bone disease diagnosis and research is an important means of detection.